The Road to Cures Series: COVID-19, Vaccinations, and Blood Cancer Patients: The LLS Registry and Q&A – Module 5 of 5

Program Overview

This activity provides a review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination in patients with blood cancer and audience Q&A.

This activity will cover the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.

Credit Expired

0.75 CE Credit(s)

Expires: March 9, 2023

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Analyze the impact of COVID-19 and its effect on therapy and outcomes in blood cancer patients

Activity Faculty

Larry A. Saltzman, MD

Executive Research Director
The Leukemia & Lymphoma Society
Rye Brook, NY

Kenneth C. Anderson, MD

Kraft Family Professor of Medicine
Harvard Medical School
Program Director, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA

Lee M. Greenberger, PhD

Chief Scientific Officer
The Leukemia & Lymphoma Society
Rye Brook, NY

Carl H. June, MD

Richard W. Vague Professor, Immunotherapy
Director, Center for Cellular Immunotherapies
Director, Parker Institute for Cancer Immunotherapy
University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Gail J. Roboz, MD

Professor, Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
Division of Hematology and Oncology
New York-Presbyterian Hospital
New York, NY

Louis M. Staudt, MD, PhD

Chief, Lymphoid Malignancies Branch
Director, Center for Cancer Genomics
National Cancer Institute
Bethesda, MD

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 